Senores Pharmaceuticals Limited has received shareholder approval for the issuance of 11,70,000 convertible equity warrants to the promoter group on a preferential basis. The special resolution was passed with a significant majority of 96.45% during the EGM held on January 31, 2026. Notably, while the resolution passed, 25.21% of institutional votes were cast against the proposal. This issuance represents a strategic capital infusion by the promoters, signaling long-term commitment to the company's growth.

Senores Pharmaceuticals Limited held an Extra-Ordinary General Meeting (EGM) on January 31, 2026, to approve a significant fundraise. The company sought shareholder approval for the issuance of 11,70,000 convertible equity warrants on a preferential basis. These warrants are being issued specifically to the Promoter and Promoter Group category, indicating a capital infusion from the company's leadership. The resolution was presented as a special resolution, and the final voting results are expected to be submitted shortly.

Senores Pharmaceuticals reported a robust Q3FY26 with consolidated revenue growing 64% YoY to ₹175 crores and PAT increasing 85% to ₹32 crores. The company's ANDA portfolio has expanded significantly from 12 to 46 approved products within a year, providing a strong pipeline for future launches. Management maintained its FY26 guidance of 50% revenue growth and 100% PAT growth, supported by the recent acquisition of Apnar Pharma. The India branded generics business also showed explosive growth, increasing six-fold during the quarter.

Senores Pharmaceuticals reported a robust Q3 FY26 with total income growing 64.1% YoY to ₹174.6 crore. Net profit (PAT) surged 104.7% YoY to ₹33.6 crore, supported by a significant 360 bps expansion in EBITDA margins to 30.9%. The company successfully completed a 75% stake acquisition in Apnar Pharmaceuticals, adding USFDA-approved facilities and 5 ANDAs to its portfolio. Regulated markets remain the primary growth driver, contributing 65% of total revenue with high EBITDA margins of 40%.

Senores Pharmaceuticals reported a stellar performance for Q3FY26, with consolidated revenue growing 64% YoY to Rs 175 crore and PAT doubling to Rs 34 crore. The company's regulated markets business remains the primary driver, contributing 64.5% of revenue with a strong 40% EBITDA margin. Significant improvement was seen in the emerging markets segment, where EBITDA margins jumped from 1% to 13% YoY. The integration of Apnar Pharmaceuticals is progressing ahead of schedule, with 75% of the stake already acquired and the remainder expected by Q2FY27.

Senores Pharmaceuticals reported a robust Q3 FY26 with a 64% YoY increase in total income to Rs 175 crore and a 105% surge in PAT to Rs 34 crore. The company's regulated markets segment grew 60.5% YoY with a strong 40% EBITDA margin, while emerging markets saw a significant margin expansion from 1% to 13%. The acquisition of Apnar Pharmaceuticals is progressing well, with 75% stake already acquired and integration happening faster than expected. With 46 approved ANDAs and over 100 strengths yet to be launched, the company maintains a strong growth pipeline.

Senores Pharmaceuticals reported a robust performance for Q3 FY26, with consolidated revenue from operations growing 69.4% YoY to ₹174.56 crore. Net profit for the quarter more than doubled, reaching ₹33.58 crore compared to ₹16.42 crore in the same period last year. The company has successfully utilized ₹362.12 crore of its ₹500 crore IPO proceeds, primarily for debt repayment and working capital. For the nine-month period ended December 2025, the company has already surpassed its total FY25 profit, indicating strong growth momentum.

Senores Pharmaceuticals has successfully completed the acquisition of a 75% majority stake in Apnar Pharma Private Limited. The company acquired 56,63,804 equity shares for a total cash consideration of ₹11.46 crore on January 16, 2026. This transaction is part of a phased acquisition strategy to eventually own 100% of the target company. The acquisition of the remaining 25% equity interest is scheduled to be completed by the second quarter of FY 2027.

Senores Pharmaceuticals has called an Extraordinary General Meeting (EGM) on January 31, 2026, to seek approval for a preferential issue of 11,70,000 convertible equity warrants. The warrants are priced at ₹812 each, aiming to raise approximately ₹95 crore exclusively from the promoter and promoter group. Allottees will pay 25% of the total consideration upfront, with the remaining 75% payable upon conversion into equity shares within 18 months. This capital infusion signifies strong promoter commitment and provides the company with significant growth capital.

Senores Pharmaceuticals has approved a preferential issue of 11.70 lakh convertible equity warrants to its promoter group at a price of ₹812 per warrant. The total fundraise amounts to approximately ₹95.00 crore, intended to strengthen the company's capital position. Promoters will contribute 25% of the amount upfront, with the balance payable upon conversion within 18 months. This issuance will increase the promoter group's stake from 23.36% to 25.26% on a fully diluted basis.

Senores Pharmaceuticals is acquiring Apnar Pharma for an enterprise value of ₹91 crores, including a USFDA-approved facility in Gujarat and five high-value ANDA assets. The transaction involves assuming ₹76 crores of debt and paying ₹15 crores in equity, funded through IPO proceeds and internal accruals. Management targets ₹100 crore revenue in FY27, with peak potential reaching ₹250 crore by FY28. This strategic move aims to optimize costs by shifting production from the US to India and tapping into a $700 million market opportunity.

Senores Pharmaceuticals has announced the 100% acquisition of Apnar Pharma Private Limited for an enterprise value of approximately Rs 91 crores. The deal includes taking over Rs 76 crores in debt and liabilities, with a cash equity contribution of Rs 15 crores funded via IPO proceeds and internal accruals. This acquisition provides Senores with a US-FDA, MHRA, and Health Canada approved manufacturing facility in Gujarat and 5 ANDAs with a total addressable market of $722 million. The transaction is expected to complete its first tranche by March 2026, facilitating backward integration and expansion into UK and Canadian markets.

Senores Pharmaceuticals, Inc. announced the approval and launch of Deferiprone Tablets USP, 500 mg & 1000 mg, which will be marketed by Dr. Reddy’s Laboratories Inc. in the US market. This product is bioequivalent and therapeutically equivalent to Ferriprox Tablets of Chiesi USA, Inc. According to symphony data, Deferiprone Tablets, 500 mg & 1000 mg brand and generic products, had U.S. sales of approximately $70 million MAT for the twelve months ending in October 2025. Senores has a portfolio of 46 ANDAs and 133 strengths along with a pipeline of 22 ANDAs and 52 strengths.

Senores Pharmaceuticals has received marketing authorizations from the Philippine FDA for 10 products across Cardiovascular, CNS, and Pain management therapies. The market size of these drugs in the Philippines is valued at US $23 million, representing a significant growth opportunity. This approval allows Senores to expand its footprint in Southeast Asia and provide affordable healthcare options. The company has 32 own ANDA and 32 CMO/CDMO commercial products permitted for distribution in the USA.